Your drug development solution provider

Model Informed Pediatric Development Applied to Bilastine: Ontogenic PK Model Development, Dose Selection for First Time in Children and PK Study Design

7 noviembre, 2017

Valvanera Vozmediano, Ander Sologuren, John C. Lukas, Nerea Leal & Mónica Rodriguez

Be the first to know about our initiatives, news and other related information

RESPONSIBLE: DYNAKIN S.L. PURPOSE: Respond to your information request. RIGHTS: You have the right to access, rectify and delete the data, as well as other rights, as explained in the additional information. ADDITIONAL INFORMATION:You can consult the additional and detailed information on Data Protection here.

I accept the terms of use.

Categories

  • No hay categorías
Contact us

We wish to know from you,
we wish to help you.

RESPONSIBLE: DYNAKIN S.L. PURPOSE: Respond to your information request. RIGHTS: You have the right to access, rectify and delete the data, as well as other rights, as explained in the additional information. ADDITIONAL INFORMATION:You can consult the additional and detailed information on Data Protection here.

I accept the terms of use.

↑